Skip to content 
BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator of the immune system and an immune checkpoint inhibitor. It has a license agreement with the University of Maryland, Baltimore County to develop and commercialize soluble CD80 as a biologic agent for the treatment of cancer. BriaCell Therapeutics Corp., has a collaboration with MSK Accelerator to accelerate theclinical development of Bria-OTS+ for multiple cancer indications including metastatic breast cancer, prostate cancer, and other cancers. The company is headquartered in West Vancouver, Canada. more
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
| BCTXL | |
|---|---|
| ROA (LTM) | 0.00% |
| ROE (LTM) | 0.00% |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
| BCTXL | |
|---|---|
| Trailing PE | NM |
| Forward PE | NM |
| P/S (TTM) | 0.00 |
| P/B | 0.00 |
| EV/R | 0.00 |
| EV/Ebitda | NM |
BriaCell Therapeutics Corp. Warrant expiring 2031 (BCTXL) share price today is $1.08
Yes, Indians can buy shares of BriaCell Therapeutics Corp. Warrant expiring 2031 (BCTXL) on Vested. To buy
Yes, you can purchase fractional shares of BriaCell Therapeutics Corp. Warrant expiring 2031 (BCTXL) via the Vested app. You can start investing in BriaCell Therapeutics Corp. Warrant expiring 2031 (BCTXL) with a minimum investment of $1.
You can invest in shares of BriaCell Therapeutics Corp. Warrant expiring 2031 (BCTXL) via Vested in three simple steps:
The 52-week high price of BriaCell Therapeutics Corp. Warrant expiring 2031 (BCTXL) is $1.4. The 52-week low price of BriaCell Therapeutics Corp. Warrant expiring 2031 (BCTXL) is $0.65.
The price-to-earnings (P/E) ratio of BriaCell Therapeutics Corp. Warrant expiring 2031 (BCTXL) is
The price-to-book (P/B) ratio of BriaCell Therapeutics Corp. Warrant expiring 2031 (BCTXL) is 0.00
The dividend yield of BriaCell Therapeutics Corp. Warrant expiring 2031 (BCTXL) is 0.00%
The market capitalization of BriaCell Therapeutics Corp. Warrant expiring 2031 (BCTXL) is
The stock symbol (or ticker) of BriaCell Therapeutics Corp. Warrant expiring 2031 is BCTXL
Consider the share price of BriaCell Therapeutics Corp. Warrant expiring 2031 as a long-term story and not a daily point list. The price represents a movement of the stock in both good and bad times when looked at over many years. This assists the investors to know whether BriaCell Therapeutics Corp. Warrant expiring 2031 has succeeded to expand steadily and overcome market declines. With this price movement observed and the way the business is progressing, it is easier to make a decision whether the stock is worth having in the long term or not.
When investing in BriaCell Therapeutics Corp. Warrant expiring 2031 shares, you are not based in India then your investment is not just based on the stock price. It is also determined by the currency movement of the dollar in relation to the rupee. When you have an appreciation of the BriaCell Therapeutics Corp. Warrant expiring 2031 stock and the dollar appreciation is also the same, you gain more in terms of rupees. When the rupee appreciated, it will lower your profits. This currency flow is a silent cause of great contribution to your ultimate returns over many years.
Rather than merely checking the share price of BriaCell Therapeutics Corp. Warrant expiring 2031 and comparing it with that of other stocks in the same sector, one can check how robust the business is. Investors tend to compare such aspects as profits, cash generation, and the stability of the revenues of the company. This means that BriaCell Therapeutics Corp. Warrant expiring 2031 stock in most cases does not react in the same manner as other companies in the sector due to its brand and services revenue.
Link copied 
